What happened

Shares of German biotech CureVac (NASDAQ:CVAC) are down by a hefty 49.9% as of 9:47 a.m. EDT Thursday morning. The biotech's shares are getting walloped today in response to disappointing late-stage trial results for its COVID-19 vaccine candidate known as CVnCoV.

Specifically, CureVac reported that the experimental vaccine completely whiffed on its second interim analysis. Despite being a messenger RNA (mRNA) vaccine, which is the same platform used to develop the Pfizer/BioNTech and Moderna vaccines, this early peek revealed that CVnCoV was less than half as effective (47%) as its predecessors at preventing COVID-19 infections. 

A doctor taking care of a COVID-19 patient.

Image source: Getty Images.

So what

CureVac blamed the vaccine's poor efficacy -- compared to other mRNA vaccines already on the market -- on the large number of COVID-19 variants currently in circulation. The first round of mRNA vaccines were trialed before most of these variants became widespread.

While the vaunted U.S. market is arguably already saturated with COVID-19 vaccines, CureVac stood a decent shot at carving out a profitable niche with its vaccine in several ex-U.S. territories. Following these underwhelming trial results, however, the biotech probably won't realize a significant financial benefit from this once-promising product candidate. 

Now what

Can CureVac stock bounce back soon? Wall Street was expecting a lot from this vaccine from a revenue generation standpoint, to put it mildly.

The biotech, in fact, may have just lost upward of $3 billion in future revenue. In other words, CureVac's shares are unlikely to rally anytime soon. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.